Cilostazol/probucol - Otsuka Pharmaceutical

Drug Profile

Cilostazol/probucol - Otsuka Pharmaceutical

Alternative Names: cilostazol 100mg/probucol 250mg; LPC-01; probucol/cilostazol

Latest Information Update: 03 Jun 2016

Price : $50

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antihyperlipidaemics; Antiplatelets; Phenols; Small molecules; Tetrazoles
  • Mechanism of Action Antioxidants; Free radical scavengers; Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 03 Jun 2016 Chemical information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top